Medsafe hasn’t yet received an application for the approval of geographic atrophy (GA) treatment Syfovre in New Zealand, despite its recent approval in Australia.

In two studies published in 2023, intravitreal injection of Syfovre (pegcetacoplan, Apellis) every second month was shown to be generally well tolerated and slowed GA progression in adults with GA secondary to age-related macular degeneration.

“Pegcetacoplan is classified as a prescription medicine in New Zealand. This means that when a medicine containing pegcetacoplan is approved, it will only be available on prescription. Medsafe has not received an application for approval of Syfovre, or any other medicine containing pegcetacoplan,” Medsafe said.